CALI BIOSCIENCES 加立生科
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Cali Biosciences Announces Publication of Successful Phase 2 Study Results in Hernia 2024-05-21 17:52
Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries 2023-06-06 00:00
Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use 2023-04-19 11:05
Cali Biosciences Announces Publications of Phase IIa Results of Long-Acting Ropivacaine (CPL-01) 2022-10-27 10:07
Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain 2022-03-22 00:00
ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine 2021-11-19 13:14
Cali Biosciences Initiates Phase 2b Study of Long-Acting Ropivacaine for Non-Opioid Treatment of Post-Operative Pain 2021-08-12 10:28
1